Regulation of 11β-hydroxysteroid dehydrogenase type 2 by diuretics and the renin–angiotensin–aldosterone axis

Ricketts, Marie‐Louise; Stewart, Paul M.

doi:10.1042/cs0960669

Cited by 16 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the effect of in vivo administration of Ang II was not described in that study. Another in vitro study demonstrated that 11bHSD type 2 activity in a human colon carcinoma cell line was reduced after incubation with Ang II at supraphysiologic concentrations and increased after incubation with several ACE inhibitors [10]. These findings are in contrast to our study, which is probably explained by differences in target tissues studied and by the mode of angiotensin administration (i.e., either through incubation of angiotensin with tissue in vitro or via systemic infusion of angiotensin in vivo).…”

Section: Discussioncontrasting

confidence: 63%

See 1 more Smart Citation

Angiotensin administration stimulates renal 11β-hydroxysteroid dehydrogenase activity in healthy men

Kerstens¹,

Kleij²,

Boonstra³

et al. 2004

Kidney International

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 63%

“…In vitro experiments have suggested that the activity of 11bHSD type 2 is inhibited by angiotensin II (Ang II) [9,10]. If extrapolated to in vivo conditions, these observations would imply that angiotensin can stimulate the mineralocorticoid receptor both by releasing aldosterone and by increasing cortisol availability in the kidney.…”

mentioning

confidence: 97%

Angiotensin administration stimulates renal 11β-hydroxysteroid dehydrogenase activity in healthy men

Kerstens¹,

Kleij²,

Boonstra³

et al. 2004

Kidney International

View full text Add to dashboard Cite

show abstract

“…That action could contribute to the antihypertensive effects of ACEI. Captopril enalapril, lisinopril and ramipril share this action, but fosinopril does not (Ricketts and Stewart, 1999; Riddle and McDaniel, 1994). We speculate that this could be one explanation for the lack of benefit of fosinopril in this model.…”

Section: Discussionmentioning

confidence: 99%

Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors

Moulder

Cohen

Fish

2014

International Journal of Radiation Biology

View full text Add to dashboard Cite

Purpose We tested five different angiotensin converting enzyme inhibitors (ACEI) as mitigators of experimental radiation nephropathy at drug doses calibrated to the plasma renin activity (PRA). This was done to determine whether all ACEI had the same efficacy as mitigators of radiation nephropathy when used at drug doses that gave equivalent suppression of the renin angiotensin system. Method 10 Gy total body irradiation with bone marrow transplantation was used to cause radiation nephropathy in barrier-maintained rats. Equivalent ACEI doses were determined based on their effect to inhibit angiotensin converting enzyme (ACE) and raise the PRA in unirradiated animals. Results PRA-equivalent doses were found for captopril, lisinopril, enalapril, ramipril and fosinopril. These doses overlap the human doses of these drugs on a body surface area basis. All ACE inhibitors, except fosinopril, mitigated radiation nephropathy; captopril was a somewhat better mitigator than lisinopril, enalapril or ramipril. Conclusions Most, but not all, ACEI mitigate radiation nephropathy at doses that overlap their clinically-used doses (on a body surface area basis). Fosinopril is known to be an ineffective mitigator of radiation pneumonitis, and it also does not mitigate radiation nephropathy. These pre-clinical data are critical in planning human studies of the mitigation of normal tissue radiation injury.

show abstract

“…An interaction between these two agents has been discussed through the mechanism of 11β-OHSD. 7,8 In this regard, the present case is the first in which the masking effect of an ACE-I on the development of pseudoaldosteronims has been described. Of note is that this development was triggered by a subtle increase of glycyrrhizin (from 200 to 240 mg).…”

Section: Discussionmentioning

confidence: 84%

Pseudoaldosteronism due to the concurrent use of two herbal medicines containing glycyrrhizin: interaction of glycyrrhizin with angiotensin-converting enzyme inhibitor

et al. 2006

View full text Add to dashboard Cite

A 77-year-old man with a history of hypertension and hyperuricemia was admitted to our hospital complaining of limb weakness, persistent constipation, and worsening hypertension. He had been taking a Chinese herbal remedy for allergic rhinitis for the past 10 years, together with an angiotensin-converting enzyme inhibitor (ACE-I; enalapril, 20 mg daily). After the dosage of enalapril had been reduced to 10 mg daily about 1(1/2) years before the current admission, he had developed persistent constipation. Therefore, he had started taking another traditional Chinese herbal remedy, a laxative, for the constipation, about 4 months prior to this hospitalization. Laboratory data on admission demonstrated marked metabolic alkalosis with severe hypokalemia associated with urinary wasting of potassium and chloride. A diagnosis of pseudoaldosteronism was made based upon his past history of exposure to various traditional Chinese medicines containing glycyrrhizin. Discontinuation of the Chinese remedies and supplementation of potassium successfully normalized the electrolyte imbalance and relieved all symptoms within a short time. The present case describes the occurrence of pseudoaldosteronism induced by a patient taking two traditional Chinese herbs, both containing glycyrrhizin, resulting in an overdose of this causative chemical agent. The development of pseudoaldosteronism appeared to be of particular interest with regard to the interaction of the renin-angiotensin-aldosterone (RAA) system with glycyrrhizin, in which an ACE-I retarded the development of pseudoaldosteronism.

show abstract

Regulation of 11β-hydroxysteroid dehydrogenase type 2 by diuretics and the renin–angiotensin–aldosterone axis

Cited by 16 publications

References 24 publications

Angiotensin administration stimulates renal 11β-hydroxysteroid dehydrogenase activity in healthy men

Angiotensin administration stimulates renal 11β-hydroxysteroid dehydrogenase activity in healthy men

Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors

Pseudoaldosteronism due to the concurrent use of two herbal medicines containing glycyrrhizin: interaction of glycyrrhizin with angiotensin-converting enzyme inhibitor

Contact Info

Product

Resources

About